Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
Several companies were in the spotlight due to various developments: Oracle ($甲骨文(ORCL.US)$) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand. Acadia Pharmaceuticals ($阿卡迪亞(ACAD.US)$) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial. Vail Resorts ($Vail Resorts(MTN.US)$) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall. $阿莎娜(ASAN.US)$Asana rep...
$阿卡迪亞(ACAD.US)$Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
ACADIA Pharmaceuticals Inc.'s low P/S ratio is due to its poor revenue outlook. Investors' gloomy expectations for future revenue growth are driving the low P/S ratio. These conditions will persist as a hurdle for the share price unless improved.
The share price gained 80% over twelve months, justified by revenue growth. If maintained, the share price could rise. However, it's advised to examine profitability trends and cash flow before deeming this growth stock underappreciated.
阿卡迪亞股票討論區
Oracle ( $甲骨文(ORCL.US)$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $阿卡迪亞(ACAD.US)$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US)$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$阿莎娜(ASAN.US)$ Asana rep...
Ouch! I’m seeing a drop coming?
T 1 News halt
🎯 Ph 3 readouts in Q1 2024...
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$ Phase 3
$Aquestive Therapeutics(AQST.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$強生(JNJ.US)$ Phase 3
Biotech Stock Catalyst Watchlist
$輝瑞(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood醫藥(IRWD.US)$ Phase 3
$阿里拉姆制藥(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...
Ph 3 readouts in Q1 2024...
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood醫藥(IRWD.US)$ Phase 3
$阿里拉姆制藥(ALNY.US)$ Phase 3
$福泰製藥(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3...
暫無評論